
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Titan Pharmaceuticals Inc (TTNP)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TTNP (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $7
1 Year Target Price $7
0 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.24% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.56M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 1.3 | 52 Weeks Range 3.03 - 14.80 | Updated Date 08/15/2025 |
52 Weeks Range 3.03 - 14.80 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -57.2% | Return on Equity (TTM) -105.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 326634 | Price to Sales(TTM) 3440.44 |
Enterprise Value 326634 | Price to Sales(TTM) 3440.44 | ||
Enterprise Value to Revenue 7.04 | Enterprise Value to EBITDA -0.92 | Shares Outstanding 1330230 | Shares Floating 521698 |
Shares Outstanding 1330230 | Shares Floating 521698 | ||
Percent Insiders 49.68 | Percent Institutions 2.04 |
Upturn AI SWOT
Titan Pharmaceuticals Inc

Company Overview
History and Background
Titan Pharmaceuticals, Inc. was founded in 1992. It is focused on the development and commercialization of proprietary therapeutics utilizing its ProNeurau00ae long-acting delivery system. Early development focused on treatments for hypothyroidism, but its focus shifted to opioid addiction with Probuphineu00ae.
Core Business Areas
- Segment Name: Pharmaceuticals: Develops and commercializes pharmaceutical products utilizing ProNeurau00ae, with a primary focus on addiction treatment. Their main area is developing products that are based on long-acting formulations.
Leadership and Structure
The leadership team is headed by a CEO and other key executives responsible for various functions such as research, development, and commercialization. The structure includes departments for clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Product Name: Probuphine: Probuphine is a subdermal implant for the maintenance treatment of opioid use disorder in patients who are stable on low-to-moderate doses of buprenorphine. Market share data is not readily available publicly. Competitors include generic buprenorphine products (pills and sublingual films from companies like Mylan, Teva) and other long-acting buprenorphine formulations like Sublocade (Indivior).
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the segment focused on addiction treatment, is characterized by high regulatory hurdles, intense competition, and a significant unmet need for effective therapies. Increasing awareness of the opioid crisis drives demand.
Positioning
Titan Pharmaceuticals is positioned as a developer of long-acting, implantable drug delivery systems for chronic diseases, especially addiction. Their advantage lies in the ProNeura technology. Titan's competitors are other pharmaceutical companies in the addiction treatment space, including those with generic medications and injectable products.
Total Addressable Market (TAM)
The opioid addiction treatment market is estimated to be worth billions of dollars annually. Titan's position relies on the adoption of long-acting treatments and their ability to capture a portion of the buprenorphine maintenance market. Specific TAM estimates vary depending on the source, but projections consistently show substantial growth potential.
Upturn SWOT Analysis
Strengths
- Proprietary ProNeurau00ae drug delivery system
- Potential for improved patient compliance with long-acting formulations
- Focus on addressing the opioid crisis
Weaknesses
- Dependence on a single product (Probuphine)
- Financial instability and history of losses
- Limited marketing and sales capabilities
- Regulatory challenges related to implantable drug delivery
Opportunities
- Expanding ProNeurau00ae platform to other therapeutic areas
- Partnerships with larger pharmaceutical companies
- Increased government funding and support for addiction treatment
- Developing next-generation ProNeura implants
Threats
- Competition from generic and branded buprenorphine products
- Regulatory setbacks or changes in reimbursement policies
- Product liability claims
- Negative perception of opioid addiction treatment
Competitors and Market Share
Key Competitors
- OTCQX:INVV
- OTCQX:BTNXF
- ENDP
Competitive Landscape
Titan faces significant competition from larger pharmaceutical companies with established buprenorphine products. Their advantage is the long-acting implantable delivery, but challenges include cost and physician/patient acceptance.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited by the slow adoption of Probuphine and the company's financial constraints.
Future Projections: Future projections are highly uncertain and depend on successful commercialization of Probuphine and potential expansion of the ProNeurau00ae platform.
Recent Initiatives: Recent initiatives likely involve efforts to secure partnerships, expand market access for Probuphine, and develop new formulations using the ProNeurau00ae technology.
Summary
Titan Pharmaceuticals is a high-risk, high-reward biotech company with a proprietary drug delivery system, ProNeura. They are primarily focused on Probuphine, an implant for opioid addiction treatment. The company faces significant financial challenges and strong competition. Successful commercialization of Probuphine and expansion of the ProNeura platform are crucial for their future. Regulatory hurdles and market acceptance of implantable treatments pose ongoing risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data may be outdated. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Titan Pharmaceuticals Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 1996-01-18 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.titanpharm.com |
Full time employees - | Website https://www.titanpharm.com |
Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.